Systematic review and meta-analysis of the efficacy of short-course antibiotic treatments for community-acquired pneumonia in adults

Antimicrobial Agents and Chemotherapy

Volumn 62, Issue 9, 2018, Pages

  Tansarli, Giannoula S ^a   Mylonakis, Eleftherios ^a  

^a BROWN UNIVERSITY   (United States)

Author keywords

Chlamydia pneumoniae; Extended; Haemophilus influenzae; Influenza; Mortality; Mycoplasma pneumoniae; Pneumonia; Prolonged; Short term; Streptococcus pneumoniae

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; AZITHROMYCIN; CEFTRIAXONE; GEMIFLOXACIN; JOSAMYCIN; LEVOFLOXACIN; ROXITHROMYCIN; TELITHROMYCIN; ANTIINFECTIVE AGENT;

ADULT; ANTIBIOTIC THERAPY; CHLAMYDIA PNEUMONIAE; CHLAMYDIAL PNEUMONIA; CLINICAL OUTCOME; COMMUNITY ACQUIRED PNEUMONIA; COMPARATIVE EFFECTIVENESS; DRUG EFFICACY; DRUG SAFETY; GASTROINTESTINAL SYMPTOM; HAEMOPHILUS INFLUENZAE; HEADACHE; HUMAN; HYPERTRANSAMINASEMIA; LONG TERM CARE; META ANALYSIS; MORTALITY RISK; MYCOPLASMA PNEUMONIA; MYCOPLASMA PNEUMONIAE; NONHUMAN; PNEUMONIA SEVERITY INDEX; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; RECURRENCE RISK; REVIEW; SHORT COURSE THERAPY; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE; SYSTEMATIC REVIEW; TREATMENT DURATION; VIRUS PNEUMONIA; CLINICAL TRIAL (TOPIC); COMMUNITY ACQUIRED INFECTION; PNEUMONIA;

ADULT; ANTI-BACTERIAL AGENTS; CLINICAL TRIALS AS TOPIC; COMMUNITY-ACQUIRED INFECTIONS; HUMANS; PNEUMONIA; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 85052221104     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00635-18     Document Type: Review

References (40)

1. Broulette J, Yu H, Pyenson B, Iwasaki K, Sato R. 2013. The incidence rate and economic burden of community-acquired pneumonia in a working-age population. Am Health Drug Benefits 6:494–503.
2. Marston BJ, Plouffe JF, File TM, Jr, Hackman BA, Salstrom SJ, Lipman HB, Kolczak MS, Breiman RF. 1997. Incidence of community-acquired pneumonia requiring hospitalization. Results of a population-based active surveillance study in Ohio. The Community-Based Pneumonia Incidence Study Group. Arch Intern Med 157:1709–1718.
3. National Center for Health Statistics, U.S. Centers for Disease Control and Prevention. 2016. Leading causes of death. National Center for Health Statistics, U.S. Centers for Disease Control and Prevention, Atlanta, GA.
4. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, Dowell SF, File TM, Jr, Musher DM, Niederman MS, Torres A, Whitney CG. 2007. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 44(Suppl 2):S27–S72. https://doi.org/10.1086/511159.
5. Lim WS, Baudouin SV, George RC, Hill AT, Jamieson C, Le Jeune I, Macfarlane JT, Read RC, Roberts HJ, Levy ML, Wani M, Woodhead MA. 2009. BTS guidelines for the management of community acquired pneumonia in adults: update 2009. Thorax 64(Suppl 3):iii1–iii55. https://doi.org/10.1136/thx.2009.121434.
6. Woodhead M, Blasi F, Ewig S, Garau J, Huchon G, Ieven M, Ortqvist A, Schaberg T, Torres A, van der Heijden G, Read R, Verheij TJ. 2011. Guidelines for the management of adult lower respiratory tract infections—summary. Clin Microbiol Infect 17(Suppl 6):S1–S24. https://doi.org/10.1111/j.1469-0691.2011.03557.x.
7. Avdic E, Cushinotto LA, Hughes AH, Hansen AR, Efird LE, Bartlett JG, Cosgrove SE. 2012. Impact of an antimicrobial stewardship intervention on shortening the duration of therapy for community-acquired pneumonia. Clin Infect Dis 54:1581–1587. https://doi.org/10.1093/cid/cis242.
8. Walsh TL, DiSilvio BE, Hammer C, Beg M, Vishwanathan S, Speredelozzi D, Moffa MA, Hu K, Abdulmassih R, Makadia JT, Sandhu R, Naddour M, Chan-Tompkins NH, Trienski TL, Watson C, Obringer TJ, Kuzyck J, Brem-mer DN. 2018. Impact of procalcitonin guidance with an educational program on management of adults hospitalized with pneumonia. Am J Med 131:201.e1–201.e8. https://doi.org/10.1016/j.amjmed.2017.08.039.
9. Bohte R, van’t Wout JW, Lobatto S, Blussé van Oud Alblas A, Boekhout M, Nauta EH, Hermans J, van den Broek PJ. 1995. Efficacy and safety of azithromycin versus benzylpenicillin or erythromycin in community-acquired pneumonia. Eur J Clin Microbiol Infect Dis 14:182–187. https:// doi.org/10.1007/BF02310353.
10. Brion JP, Sedallian A, Le Noc P, Briffod J, Micoud M. 1990. Azithromycin versus josamycin: treatment of 89 cases of acute pneumonia. Pathol Biol (Paris) 38(Pt 2):521–525. (In French).
11. D’Ignazio J, Camere MA, Lewis DE, Jorgensen D, Breen JD. 2005. Novel, single-dose microsphere formulation of azithromycin versus 7-day levofloxacin therapy for treatment of mild to moderate community-acquired pneumonia in adults. Antimicrob Agents Chemother 49:4035–4041. https://doi.org/10.1128/AAC.49.10.4035-4041.2005.
12. Drehobl MA, De Salvo MC, Lewis DE, Breen JD. 2005. Single-dose azithromycin microspheres vs clarithromycin extended release for the treatment of mild-to-moderate community-acquired pneumonia in adults. Chest 128:2230–2237. https://doi.org/10.1378/chest.128.4.2230.
13. Dunbar LM, Wunderink RG, Habib MP, Smith LG, Tennenberg AM, Khashab MM, Wiesinger BA, Xiang JX, Zadeikis N, Kahn JB. 2003. High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm. Clin Infect Dis 37:752–760. https://doi.org/10.1086/377539.
14. el Moussaoui R, de Borgie CA, van den Broek P, Hustinx WN, Bresser P, van den Berk GE, Poley JW, van den Berg B, Krouwels FH, Bonten MJ, Weenink C, Bossuyt PM, Speelman P, Opmeer BC, Prins JM. 2006. Effectiveness of discontinuing antibiotic treatment after three days versus eight days in mild to moderate-severe community acquired pneumonia: randomised, double blind study. BMJ 332:1355. https://doi.org/10.1136/bmj.332.7554.1355.
15. File TM, Jr, Mandell LA, Tillotson G, Kostov K, Georgiev O. 2007. Gemifloxacin once daily for 5 days versus 7 days for the treatment of community-acquired pneumonia: a randomized, multicentre, double-blind study. J Antimicrob Chemother 60:112–120. https://doi.org/10.1093/jac/dkm119.
16. Gris P. 1996. Once-daily, 3-day azithromycin versus a three-times-daily, 10-day course of co-amoxiclav in the treatment of adults with lower respiratory tract infections: results of a randomized, double-blind comparative study. J Antimicrob Chemother 37(Suppl C):93–101.
17. Kinasewitz G, Wood RG. 1991. Azithromycin versus cefaclor in the treatment of acute bacterial pneumonia. Eur J Clin Microbiol Infect Dis 10:872–877. https://doi.org/10.1007/BF01975846.
18. Léophonte P, Choutet P, Gaillat J, Petitpretz P, Portier H, Montestruc F, Pecking M, De Bels F. 2002. Efficacité comparée de la ceftriaxone dans un traitement de dix jours versus un traitement raccourci de cinq jours des pneumonies aigues communautaires de l’adulte hospitalisé avec facteur de risque. Med Mal Infect 32:369 –381.
19. O’Doherty B, Muller O. 1998. Randomized, multicentre study of the efficacy and tolerance of azithromycin versus clarithromycin in the treatment of adults with mild to moderate community-acquired pneumonia. Azithromycin Study Group. Eur J Clin Microbiol Infect Dis 17: 828–833. https://doi.org/10.1007/s100960050201.
20. Paris R, Confalonieri M, Dal Negro R, Ligia GP, Mos L, Todisco T, Rastelli V, Perna G, Cepparulo M. 2008. Efficacy and safety of azithromycin 1 g once daily for 3 days in the treatment of community-acquired pneumonia: an open-label randomised comparison with amoxicillin-clavulanate 875/125 mg twice daily for 7 days. J Chemother 20:77–86. https://doi.org/10.1179/joc.2008.20.1.77.
21. Rahav G, Fidel J, Gibor Y, Shapiro M. 2004. Azithromycin versus comparative therapy for the treatment of community acquired pneumonia. Int J Antimicrob Agents 24:181–184. https://doi.org/10.1016/j.ijantimicag.2004.01.011.
22. Rizzato G, Montemurro L, Fraioli P, Montanari G, Fanti D, Pozzoli R, Magliano E. 1995. Efficacy of a three day course of azithromycin in moderately severe community-acquired pneumonia. Eur Respir J 8:398–402. https://doi.org/10.1183/09031936.95.08030398.
23. Schönwald S, Barsic B, Klinar I, Gunjaca M. 1994. Three-day azithromycin compared with ten-day roxithromycin treatment of atypical pneumonia. Scand J Infect Dis 26:706–710. https://doi.org/10.3109/00365549409008639.
24. Schönwald S, Gunjaca M, Kolacny-Babic L, Car V, Gosev M. 1990. Comparison of azithromycin and erythromycin in the treatment of atypical pneumonias. J Antimicrob Chemother 25(Suppl A):123–126. https://doi.org/10.1093/jac/25.suppl_A.123.
25. Sopena N, Martinez-Vazquez C, Rodriguez-Suarez JR, Segura F, Valencia A, Sabrià M. 2004. Comparative study of the efficacy and tolerance of azithromycin versus clarithromycin in the treatment of community-acquired pneumonia in adults. J Chemother 16:102–103. https://doi.org/10.1179/joc.2004.16.1.102.
26. Tellier G, Niederman MS, Nusrat R, Patel M, Lavin B. 2004. Clinical and bacteriological efficacy and safety of 5 and 7 day regimens of telithromycin once daily compared with a 10 day regimen of clarithromycin twice daily in patients with mild to moderate community-acquired pneumonia. J Antimicrob Chemother 54:515–523. https://doi.org/10.1093/jac/dkh356.
27. Zhao T, Chen LA, Wang P, Tian G, Ye F, Zhu H, He B, Zhang B, Shao C, Jie Z, Gao X, Wang D, Song W, Pan Z, Chen J, Zhang X, Gao Z, Chen P, Liu Y. 2016. A randomized, open, multicenter clinical study on the short course of intravenous infusion of 750 mg of levofloxacin and the sequential standard course of intravenous infusion/oral administration of 500 mg of levofloxacin for treatment of community-acquired pneumonia. J Thorac Dis 8:2473–2484. https://doi.org/10.21037/jtd.2016.08.30.
28. Masiá M, Padilla S, Ortiz de la Tabla V, Gonzalez M, Bas C, Gutiérrez F. 2017. Procalcitonin for selecting the antibiotic regimen in outpatients with low-risk community-acquired pneumonia using a rapid point-of-care testing: a single-arm clinical trial. PLoS One 12:e0175634. https://doi.org/10.1371/journal.pone.0175634.
29. Sánchez F, Mensa J, Martinez JA, García E, Marco F, González J, Marcos MA, Soriano A, Torres A. 2003. Is azithromycin the first-choice macrolide for treatment of community-acquired pneumonia? Clin Infect Dis 36: 1239–1245. https://doi.org/10.1086/374846.
30. Food and Drug Administration. 2016. What is a serious adverse event? Food and Drug Administration, Silver Spring, MD.
31. Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE, Coley CM, Marrie TJ, Kapoor WN. 1997. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 336: 243–250. https://doi.org/10.1056/NEJM199701233360402.
32. Lim WS, van der Eerden MM, Laing R, Boersma WG, Karalus N, Town GI, Lewis SA, Macfarlane JT. 2003. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 58:377–382. https://doi.org/10.1136/thorax.58.5.377.
33. Dimopoulos G, Matthaiou DK, Karageorgopoulos DE, Grammatikos AP, Athanassa Z, Falagas ME. 2008. Short- versus long-course antibacterial therapy for community-acquired pneumonia: a meta-analysis. Drugs 68:1841–1854. https://doi.org/10.2165/00003495-200868130-00004.
34. Li JZ, Winston LG, Moore DH, Bent S. 2007. Efficacy of short-course antibiotic regimens for community-acquired pneumonia: a meta-analysis. Am J Med 120:783–790. https://doi.org/10.1016/j.amjmed.2007.04.023.
35. File TM, Jr. 2004. Clinical efficacy of newer agents in short-duration therapy for community-acquired pneumonia. Clin Infect Dis 39(Suppl 3):S159–S164. https://doi.org/10.1086/421354.
36. Kardas P. 2002. Patient compliance with antibiotic treatment for respiratory tract infections. J Antimicrob Chemother 49:897–903. https://doi.org/10.1093/jac/dkf046.
37. Verhagen AP, de Vet HC, de Bie RA, Kessels AG, Boers M, Bouter LM, Knipschild PG. 1998. The Delphi list: a criteria list for quality assessment of randomized clinical trials for conducting systematic reviews developed by Delphi consensus. J Clin Epidemiol 51:1235–1241. https://doi.org/10.1016/S0895-4356(98)00131-0.
38. Cochrane Community. 2014. Review Manager (RevMan) v 5.3. The Nordic Cochrane Centre, The Cochrane Collaboration, Copenhagen, Denmark. https://community.cochrane.org/help/tools-and-software/revman-5.
39. Mantel N, Haenszel W. 1959. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22:719–748.
40. DerSimonian R, Laird N. 1986. Meta-analysis in clinical trials. Control Clin Trials 7:177–188. https://doi.org/10.1016/0197-2456(86)90046-2.